NATCOPHARM - Swing Trade Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Swing Trade Rating: 4.3

📊 Technical & Momentum Analysis

Current Price (₹958) is slightly above 50 DMA (₹942) but below 200 DMA (₹1,013) — early signs of recovery.

MACD (16.0) — bullish crossover, momentum building.

RSI (48.2) — neutral zone, potential for upward move.

Volume: Below 1-week average — needs confirmation via rising volume.

📈 Fundamental Overview

Valuation

P/E (9.11) vs Industry P/E (34.0) — deeply undervalued.

PEG Ratio (0.07) — extremely attractive, suggests strong growth at low price.

Profitability

ROCE (32.8%) and ROE (28.0%) — excellent efficiency and returns.

EPS (₹105) — robust earnings.

Quarterly Performance

PAT Qtr: ₹406 Cr vs Prev Qtr: ₹132 Cr — major jump (Qtr Profit Var: +5.10% YoY, but QoQ surge is notable).

Dividend Yield (0.99%) — modest, adds holding comfort.

Debt-to-Equity (0.04) — virtually debt-free, strong balance sheet.

FII/DII Holding

FII down (-1.97%) — cautious foreign sentiment.

DII up (+0.17%) — mild domestic interest.

✅ Swing Trade Strategy

Optimal Entry Price: ₹940–₹955 (near 50 DMA and RSI support).

Target Exit Price: ₹1,020–₹1,050 (approaching 200 DMA and resistance zone).

Stop Loss: ₹915 (below recent swing low and psychological support).

🧭 If You Already Hold the Stock

Hold with a target of ₹1,020–₹1,050.

Exit if price falls below ₹915 or MACD momentum reverses with volume drop.

Edit in a page